ALNYLAM PHARMACEUTICALS, INC. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Alnylam Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2011 to Q4 2023.
  • Alnylam Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $2.82B, a 28.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $2.82B +$624M +28.4% Dec 31, 2023 10-K 2024-02-15
Q4 2022 $2.19B +$385M +21.3% Dec 31, 2022 10-K 2024-02-15
Q4 2021 $1.81B +$459M +34% Dec 31, 2021 10-K 2023-02-23
Q4 2020 $1.35B +$304M +29% Dec 31, 2020 10-K 2022-02-10
Q4 2019 $1.05B +$186M +21.6% Dec 31, 2019 10-K 2021-02-11
Q4 2018 $860M +$172M +25% Dec 31, 2018 10-K 2020-02-13
Q4 2017 $688M +$113M +19.6% Dec 31, 2017 10-K 2019-02-14
Q4 2016 $575M +$178M +44.7% Dec 31, 2016 10-K 2018-02-15
Q4 2015 $397M +$129M +48.1% Dec 31, 2015 10-K 2017-02-15
Q4 2014 $268M +$46M +20.7% Dec 31, 2014 10-K 2016-02-12
Q4 2013 $222M +$29.7M +15.4% Dec 31, 2013 10-K 2015-02-13
Q4 2012 $193M +$38.3M +24.8% Dec 31, 2012 10-K 2014-02-20
Q4 2011 $154M Dec 31, 2011 10-K 2013-02-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.